Synapse - GME, Medicine

Results (46)

Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses

Journal Article

Lyudovyk, O.; Kim, J. Y.; Qualls, D.; Hwee, M. A.; Lin, Y. H.; Boutemine, S. R.; Elhanati, Y.; Solovyov, A.; Douglas, M.; Chen, E.; more...
Cancer Cell (2022)

Fulltext@MSK | Save

The effect of neutropenia and filgrastim (G-CSF) on cancer patients with coronavirus disease 2019 (COVID-19) infection

Journal Article

Zhang, A. W.; Morjaria, S.; Kaltsas, A.; Hohl, T. M.; Parameswaran, R.; Patel, D.; Zhou, W.; Predmore, J.; Perez-Johnston, R.; Jee, J.; more...
Clinical Infectious Diseases (2022)

Fulltext@MSK | Save

Atypical pathogens presenting with pulmonary consolidations detected by cell-free DNA next-generation sequencing in patients with hematologic malignancies

Review

Caldararo, M.; Algazaq, J.; Schmidt, E.; Joanow, A.; Mariano, A.; Predmore, J.; Politikos, I.; Cho, C.; Stein, E. M.; Wen, X.; more...
Infectious Diseases in Clinical Practice (2022)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
Blood (2021)

Fulltext@MSK | Save

Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax

Meeting Abstract

Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach

Meeting Abstract

Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Research Letter

Roeker, L. E.; Knorr, D. A.; Thompson, M. C.; Nivar, M.; Lebowitz, S.; Peters, N.; Deonarine, I. Jr; Momotaj, S.; Sharan, S.; Chanlatte, V.; more...
Leukemia (2021)

Fulltext@MSK | Save